No profile data available.
Novo Nordisk A/S (NVO) is a healthcare company in the blood sugar management drugs industry, based in Bagsvaerd, Denmark, with about 66,700 full-time employees.
It reported revenue of 309.06 billion DKK for fiscal year 2025, up 6.4% from fiscal year 2024, and net income of 102.43 billion DKK. In Q2 2026 (the quarter ended June 30, 2026) revenue was 78.49 billion DKK, up 2.1% from a year before. North America was its largest region in fiscal year 2023, with 63% of revenue. Its market capitalization was $170.57 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S reported 309.06 billion DKK in revenue for fiscal year 2025, up 6.4% from 290.40 billion DKK in fiscal year 2024. In Q2 2026 revenue was 78.49 billion DKK.
North America: 63% of revenue by region in fiscal year 2023, followed by EMEA (24%).
$170.57 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood sugar management drugs) include Eli Lilly and Company (LLY), Oramed Pharmaceuticals Inc. (ORMP), Biomea Fusion, Inc. (BMEA), Vicapsys Life Sciences, Inc. (VICP).